IL17A and neoplasm: To assess the efficacy of IL‐17A targeting therapeutics in preventing HCC progression, we administered secukinumab (Langley et al., 2014), an anti‐human IL‐17A monoclonal antibody approved for several inflammatory disorders, to treat an orthotopic implantation tumour model in combination with sorafenib.